Gene · 3977
NIH grants1,398
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 1,398
Download this page as JSON| Grant | Title | LIFR papers | Newest fiscal year |
|---|---|---|---|
| R01CA109182 | Functional Determinants of Metastatic Dormancy | 1 | 2025 |
| R01CA120813 | Modulation of Microglia and T Cell Interactions in Malignant Glioma | 1 | 2025 |
| R01CA140337 | Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation | 1 | 2025 |
| R01CA157644 | Central tolerance mechanisms in B-cell malignancies | 1 | 2025 |
| R01CA176111 | Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance | 1 | 2025 |
| R01CA197296 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | 1 | 2025 |
| R01CA224550 | Glutamine synthetase in beta-catenin driven hepatocellular carcinoma | 1 | 2025 |
| R01CA228137 | Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis | 1 | 2025 |
| R01CA238317 | Lipid programs in melanocyte transformation | 1 | 2025 |
| R01CA249528 | Chemotherapy-driven evolution of the vascular secretome and its role in therapeutic resistance | 1 | 2025 |
| R01CA252224 | Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure | 1 | 2025 |
| R01CA260838 | The role of leukemia inhibitory factor in colorectal cancer | 1 | 2025 |
| R01CA261925 | Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer | 1 | 2025 |
| R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 1 | 2025 |
| R01DE023222 | Mutations and Target Genes in Adenoid Cystic Carcinoma | 1 | 2025 |
| R01DK118072 | Developing Effective Approaches to Extend Hematopoietic Healthspan by Targeting Cell-Extrinsic and Cell-Intrinsic Alterations at Middle Age | 1 | 2025 |
| R01DK124223 | Oxytocin as a Neuroendocrine Therapy for Obesity in Youth | 1 | 2025 |
| R01DK134489 | Distinct Glycophenotypes with Abnormal Signaling Define a Subpopulation of B cells Responsible for Production of Galactose-Deficient IgA1, the Main Autoantigen in IgA Nephropathy | 1 | 2025 |
| R01DK136327 | Molecular Determinants of liver sinusoidal endothelial cells for hepatic regeneration | 1 | 2025 |
| R01ES030113 | Circadian clock disruption: A risk factor for environmental carcinogenesis | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3977/grants?page=9